- Eli Lilly has a rich R&D pipeline, with a current active focus on diabetes which has a growing market in the US and internationally.
- The recent research results of Dulaglutide prove the company’s constant efforts to launch innovative drugs.
- Strong acquisitions in the animal health segment have helped the company move the ladder of success at a faster pace.
- Following the intended takeover, Eli Lilly has become the second largest animal health player by revenue.
- In light of the efforts put in by Eli Lilly, it has bright future prospects.